# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K190675   
B Applicant Siemens Healthcare Diagnostics, Inc.   
C Proprietary and Established Names Dimension EXL High-Sensitivity Troponin I (TNIH) Assay   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>MMI</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1215 -CreatinePhosphokinase/Creatine Kinase OrIsoenzymes TestSystem</td><td rowspan=1 colspan=1>CH - ClinicalChemistry</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New Device   
B Measurand: Cardiac troponin I (cTnI)   
C Type of Test: Quantitative Immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.   
B Indication(s) for Use: The Dimension EXL High-Sensitivity Troponin I (TNIH) assay is for in vitro diagnostic use in the quantitative measurement of cardiac troponin I in human plasma using the Dimension EXL integrated chemistry system with LOCI module. The assay can be used to aid in the diagnosis of acute myocardial infarction (AMI).   
C Special Conditions for Use Statement(s): Rx - for prescription use only For in vitro diagnostic use   
D Special Instrument Requirements: Dimension® EXLTM with LM Integrated Chemistry System

# IV Device/System Characteristics:

# A Device Description:

The Dimension EXL TNIH assay is a homogeneous, sandwich chemiluminescent immunoassay based on $\mathrm { L O C I @ }$ technology. The LOCI reagents include two synthetic bead reagents and two biotinylated anti-cardiac troponin I monoclonal antibody fragments. The first bead reagent (Sensibeads) is coated with streptavidin and contains photosensitizer dye. The second bead reagent (Chemibeads) is coated with a third anti- cardiac troponin I monoclonal antibody and contains chemiluminescent dye. The sample is incubated with Chemibeads and biotinylated antibodies to form bead-cardiac troponin I- biotinylated antibody sandwiches. Sensibeads are added and bind to the biotin to form bead-pair immunocomplexes. Illumination of the complex at $6 8 0 \mathrm { n m }$ generates singlet oxygen from Sensibeads which diffuses into the Chemibeads, triggering a chemiluminescent reaction. The resulting signal is measured at $6 1 2 \mathrm { n m }$ and is a direct function of the cardiac troponin I concentration in the sample.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Elecsys Troponin T Gen 5 STAT Assay B Predicate 510(k) Number(s): K162895

C Comparison with Predicate(s):   

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>K190675</td><td rowspan=1 colspan=1>K162895</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>Dimension EXL High-Sensitivity Troponin I(TNIH) Assay</td><td rowspan=1 colspan=1>Elecsys Troponin T Gen5 STAT</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Similarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>The immunoassay isintended to aid in thediagnosis of acutemyocardial infarction.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Differences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Device Technology:</td><td rowspan=1 colspan=1>Homogeneouschemiluminescentimmunoassay</td><td rowspan=1 colspan=1>Electrochemiluminescenceimmunoassay</td></tr></table>

# VI Standards/Guidance Documents Referenced:

Clinical and Laboratory Standards Institute (CLSI) EP05-A3: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Third Edition

CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline

CLSI EP07-A2: Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition

CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline

# VII Performance Characteristics (if/when applicable):

# 1. Analytical Performance:

a. Precision/Reproducibility:

The sponsor provided results from precision studies across multiple reagent lots. Native pooled plasma samples and one quality control sample (QC) were tested on one instrument two times a day, each with two replicates, for 20 days, for a total of 80 measurements per sample. Analysis of variance (ANOVA) was used to evaluate the data following recommendations in the Clinical and Laboratory Standards Institute (CLSI) EP05-A3 guideline, Evaluation of Precision of Quantitative Measurement Procedures; Approved

Guideline – Third Edition. Testing was repeated for 3 reagent lots. Results from one representative lot of the three lots tested, are described in the table below. The within-lab precision estimate described in the table is a total of within-run variability, within-day, between-run variability, and day-to-day variability.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Meanpg/mL</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-Lab</td></tr><tr><td rowspan=1 colspan=1>SD pg/mL</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD pg/mL</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>48.0</td><td rowspan=1 colspan=1>1.11</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>155.7</td><td rowspan=1 colspan=1>2.75</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>4.62</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>QC</td><td rowspan=1 colspan=1>7,411.7</td><td rowspan=1 colspan=1>145.59</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>246.56</td><td rowspan=1 colspan=1>3.3</td></tr></table>

The sponsor tested additional native plasma samples as described above and the results of a representative lot are summarized below:

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Meanpg/mL</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-Lab</td></tr><tr><td rowspan=1 colspan=1>SD pg/mL</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD pg/mL</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>46.1</td><td rowspan=1 colspan=1>1.28</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>1.46</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>71.8</td><td rowspan=1 colspan=1>1.45</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.09</td><td rowspan=1 colspan=1>2.9</td></tr></table>

The sponsor evaluated lot-to-lot imprecision in this study and the results reported were similar to the repeatability estimates described above.

The sponsor also evaluated site-to-site reproducibility following the recommendations in CLSI EP05-A3. Imprecision was evaluated using seven samples spanning the measurement range of the assay and comprising of native pooled lithium heparin patient samples across three sites using one lot of reagents. Testing was performed over five days, with two runs a day and three replicates per sample per run for a total n of 30 per site for each sample. The reproducibility estimate is a total of within-run variability, within-day variability, betweenrun variability, day-to-day variability, and site-to-site variability. The sample at the upper end of the assay measuring range was prepared by spiking normal human plasma with human troponin complex to desired test levels.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Conc(pg/mL)</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-Lab</td><td rowspan=1 colspan=2>Reproducibility</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>49.1</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>65.9</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>220.4</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>1,719.9</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>25.6</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>45.3</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>66.0</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>8,905.9</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>213.8</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>347.1</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>513.2</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>18,019.6</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>747.2</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>910.6</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>1,301.3</td><td rowspan=1 colspan=1>7.2</td></tr></table>

# b. Linearity:

Linearity was evaluated following the recommendations in the CLSI EP06- A guideline, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach;

Approved Guideline, with 16 lithium heparin plasma samples ranging in concentrations from $< 2 . 7 \ \mathrm { p g / m L }$ to $> 2 5 , 0 0 0 ~ \mathrm { p g / m L }$ . The high samples and the low samples were native and the intermediate samples were prepared by mixing high and low concentration samples. At least five replicates were measured for each sample, and the mean of these replicates was used to calculate the reported results. Deviations from linearity within the claimed range were never observed to be greater than $10 \%$ .

The measuring range is $4 . 0 - 2 5 , 0 0 0 \mathrm { p g / m L }$ with the upper end of the measuring range being defined by the upper linear range of the assay. See detection limits in Section VII.1.d. below for information supporting the lower end of the measuring range.

Hook Effect The sponsor demonstrated that there is no hook effect with the assay up to $1 , 2 9 6 , 0 8 0 \ : \mathrm { p g / m L }$ .

Dilution Recovery The sponsor provided dilution studies which supported the measurement of samples above the measurement range diluted by a factor of 2 and a factor of 5.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The sponsor’s traceability scheme was reviewed and found acceptable. The assay is traceable to a commercially available troponin assay.

d. Detection Limit:

Limit of Blank (LoB) Test Protocol

The LoB was determined as described in the CLSI EP17-A2 guideline, Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline – Second Edition. Testing was performed using three lots of reagents, each on one instrument. 60 determinations were obtained by testing five samples with no analyte (the zero level calibrator material) four times a day for three days across three reagent lots. LoB was calculated non-parametrically. The largest estimate across all reagent lot-instrument combinations tested was $1 . 0 \ : \mathrm { p g / m L }$ .

# Limit of Detection (LoD) Test Protocol

The LoD was determined following the recommendations in the CLSI EP17-A2 guideline. Testing was performed using three reagent lots and one instrument. For the three lots tested, seven to ten native low analyte lithium heparin plasma samples were tested every day, respectively, with four replicates for each test, for three days.

The nonparametric approach described in EP17-A2 was followed to determine the LoD. The largest estimate across all reagent lot-instrument combinations tested was $1 . 8 ~ \mathrm { p g / m L }$ .

The Limit of Quantitation (LoQ) was determined as the analyte level with a within- lab CV of less than or equal to $20 \%$ following the recommendations in the CLSI EP17-A2 guideline. Testing was completed two times a day $( \mathrm { n } { = } 2 )$ for at least 20 days for a total of 80 replicates with eight to 10 native lithium heparin plasma pools measured on one instrument using three reagent lots. For each reagent lot-instrument combination, the within-laboratory precision for each sample, expressed as $\% C V$ , was plotted against the mean concentration obtained for each sample. LoQ was determined by this precision profile as the concentration where the $\% C V$ was less than $20 \%$ . The largest estimate across all reagent lot-instrument combinations tested was $2 . 4 ~ \mathrm { p g / m L }$ .

The sponsor claims a LoB of $1 . 1 \ \mathrm { p g / m L }$ , and LoD of $2 . 7 \ : \mathrm { p g / m L }$ , and an LoQ of $4 . 0 \ : \mathrm { p g / m L }$

# e. Analytical Specificity:

Endogenous interference studies were performed following the recommendations in the CLSI EP07-A2 guideline, Interference Testing in Clinical Chemistry – Second Edition. Two sample pools were tested. One sample pool had $2 0 – 6 0 ~ \mathrm { p g / m L }$ cTnI and the second sample pool had $7 0 0 { - } 2 0 0 0 \ \mathrm { p g / m L }$ cTnI. These sample pools were spiked with potential interferents. Test results from samples spiked with the potential interferent were compared to test results from the control samples lacking the potential interferent. At the tested concentrations, these compounds caused $< 1 0 \%$ interference.

<table><tr><td rowspan=1 colspan=1>Endogenous Substance</td><td rowspan=1 colspan=1>Highest Concentration Tested WithoutSignificant Interference</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (Conjugated)</td><td rowspan=1 colspan=1>30 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (Unconjugated)</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>3000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>300 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>400 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Protein (Albumin)</td><td rowspan=1 colspan=1>6 g/dL</td></tr><tr><td rowspan=1 colspan=1>Protein (Gamma Globulin)</td><td rowspan=1 colspan=1>2.5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Protein (Total)</td><td rowspan=1 colspan=1>12 g/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid factor (RF)</td><td rowspan=1 colspan=1>1500 IU/mL</td></tr></table>

The same protocol described above was used to evaluate potential interference from therapeutic drugs. The results are summarized below. At the tested concentrations, all drugs caused $< 1 0 \%$ interference.

<table><tr><td colspan="1" rowspan="1">Drug</td><td colspan="1" rowspan="1">Highest Concentration Tested WithoutSignificant Interference</td></tr><tr><td colspan="1" rowspan="1">Abciximab</td><td colspan="1" rowspan="1">4.0 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">1324 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">3.62 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Allopurinol</td><td colspan="1" rowspan="1">294 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Amiodarone</td><td colspan="1" rowspan="1">8.92 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">152 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid</td><td colspan="1" rowspan="1">342 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Atenolol</td><td colspan="1" rowspan="1">37.6 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">308 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Captopril</td><td colspan="1" rowspan="1">23 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">1546 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Cinnarizine</td><td colspan="1" rowspan="1">67.8 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Clopidogrel</td><td colspan="1" rowspan="1">233 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Cocaine</td><td colspan="1" rowspan="1">33 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">7.8 nmol/L</td></tr><tr><td colspan="1" rowspan="1">Digitoxin</td><td colspan="1" rowspan="1">78.4 nmol/L</td></tr><tr><td colspan="1" rowspan="1">Diltiazem</td><td colspan="1" rowspan="1">15 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Disopyramide</td><td colspan="1" rowspan="1">29.5 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Dopamine</td><td colspan="1" rowspan="1">5.87 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Doxycycline</td><td colspan="1" rowspan="1">67.5 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">81.6 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">181 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">2425 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Isosorbide Dinitrate</td><td colspan="1" rowspan="1">636 nmol/L</td></tr><tr><td colspan="1" rowspan="1">Lisinopril</td><td colspan="1" rowspan="1">0.74 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Lovastatin</td><td colspan="1" rowspan="1">197.8 nmol/L</td></tr><tr><td colspan="1" rowspan="1">Low MW Heparin</td><td colspan="1" rowspan="1">2.0 U/mL</td></tr><tr><td colspan="1" rowspan="1">Methotrexate</td><td colspan="1" rowspan="1">2 mmol/L</td></tr><tr><td colspan="1" rowspan="1">Methyldopa</td><td colspan="1" rowspan="1">71 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Methylprednisolone</td><td colspan="1" rowspan="1">106.8 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Mexiletine</td><td colspan="1" rowspan="1">22.3 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">6.2 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">1156 nmol/mL</td></tr><tr><td colspan="1" rowspan="1">Nitroglycerine</td><td colspan="1" rowspan="1">704.5 nmol/L</td></tr><tr><td colspan="1" rowspan="1">Nitrofurantoin</td><td colspan="1" rowspan="1">16.8 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">431 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">198 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Primidone</td><td colspan="1" rowspan="1">183 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Propranolol</td><td colspan="1" rowspan="1">7.71 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Quinidine</td><td colspan="1" rowspan="1">37 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Simvastatin</td><td colspan="1" rowspan="1">76.5 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Theophylline</td><td colspan="1" rowspan="1">222 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Thyroxine</td><td colspan="1" rowspan="1">6 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Tissue Plasminogen Activator</td><td colspan="1" rowspan="1">2.3 μg/mL</td></tr><tr><td colspan="1" rowspan="1">Trimethoprim</td><td colspan="1" rowspan="1">138.3 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">4.4 μmol/L</td></tr><tr><td colspan="1" rowspan="1">Warfarin</td><td colspan="1" rowspan="1">32.5 μmol/L</td></tr></table>

# Cross-Reactivity

Potential cross-reactivity was evaluated following the recommendations in the CLSI guideline EP07-A2.

To evaluate cross reactivity, the substances shown in the following table were added to lithium heparin plasma patient samples at two cTnI concentrations $( \sim 0 \mathrm { a n d } \sim 4 0 \mathrm { p g / m L } )$ . Test results from samples spiked with the cross-reactant were compared to test results from samples without cross-reactant added. Samples were measured using three lots. The sponsor claims that at the tested concentrations, these compounds caused $< 0 . 0 0 3 \%$ cross-reactivity.

<table><tr><td rowspan=1 colspan=1>Potential Cross-Reacting Substance</td><td rowspan=1 colspan=1>Highest concentration tested (ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Cardiac Troponin T</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Skeletal Troponin I</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Tropomyosin</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Actin</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Troponin C</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Myosin Light Chain</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>Myoglobin</td><td rowspan=1 colspan=1>1000</td></tr><tr><td rowspan=1 colspan=1>CK-MB</td><td rowspan=1 colspan=1>1000</td></tr></table>

# Biotin Interference

Biotin interference was tested up to $1 2 0 0 ~ \mathrm { { n g / m L } }$ in plasma samples at troponin concentrations of approximately $4 0 ~ \mathrm { p g / m L }$ and approximately $1 { , } 3 5 0 \ \mathrm { p g / m L }$ . Test results from samples spiked with biotin were compared to test results from the control samples lacking biotin. Interference was defined as a difference $5 \pm 1 0 \%$ of the control sample values. The results are summarized in the tables below:

<table><tr><td rowspan=1 colspan=1>BiotinConcentration</td><td rowspan=1 colspan=1>cTnI(pg/mL)</td><td rowspan=1 colspan=1>Bias</td></tr><tr><td rowspan=2 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>30.6</td><td rowspan=1 colspan=1>-3%</td></tr><tr><td rowspan=1 colspan=1>992.2</td><td rowspan=1 colspan=1>-5%</td></tr><tr><td rowspan=2 colspan=1>360 ng/mL</td><td rowspan=1 colspan=1>36.7</td><td rowspan=1 colspan=1>-10%</td></tr><tr><td rowspan=1 colspan=1>1175.5</td><td rowspan=1 colspan=1>-10%</td></tr><tr><td rowspan=2 colspan=1>480 ng/mL</td><td rowspan=1 colspan=1>36.7</td><td rowspan=1 colspan=1>-15%</td></tr><tr><td rowspan=1 colspan=1>1175.5</td><td rowspan=1 colspan=1>-11%</td></tr><tr><td rowspan=2 colspan=1>840 ng/mL</td><td rowspan=1 colspan=1>36.7</td><td rowspan=1 colspan=1>-67%</td></tr><tr><td rowspan=1 colspan=1>1175.5</td><td rowspan=1 colspan=1>-35%</td></tr><tr><td rowspan=2 colspan=1>1200 ng/mL</td><td rowspan=1 colspan=1>36.7</td><td rowspan=1 colspan=1>-79%</td></tr><tr><td rowspan=1 colspan=1>1175.5</td><td rowspan=1 colspan=1>-84%</td></tr></table>

The labeling states:

See limitations section for information regarding patients with either renal impairment or multiple sclerosis. Some studies have shown that serum concentrations of biotin can reach $3 5 5 ~ \mathrm { { n g / m L } }$ within the first hour after biotin ingestion for apparently healthy subjects consuming supplements of $2 0 \mathrm { m g }$ biotin per day and plasma concentrations of biotin can reach up to $1 , 1 6 0 ~ \mathrm { n g / m L }$ for apparently healthy subjects after a single dose of $3 0 0 \mathrm { m g }$ biotin.

# Limitations

The following limitations are included in the labeling:

Testing specimens from renal dysfunction patients taking biotin may lead to false negative results. Therefore, do not use this device in patients with renal impairment $\mathrm { \ e G F R { < } } 6 0 )$ , unless it is confirmed that the patient is not taking biotin.

Patients taking more than $2 0 \mathrm { m g / d a y }$ of biotin may have falsely negative results and should not use this test. There have been reports of multiple sclerosis patients taking biotin doses exceeding $2 0 \mathrm { m g / d a y }$ . Therefore, do not use this device in patients with Multiple Sclerosis, unless it is confirmed that the patient is not taking more than $2 0 \mathrm { m g / }$ day of biotin.

Patient samples may contain cardiac troponin-specific autoantibodies that could react in immunoassays to give depressed results. A test result that is inconsistent with the clinical picture and patient history should be interpreted with caution.

Samples from patients receiving preparations of mouse monoclonal antibodies for therapy or diagnosis may contain human anti-mouse antibodies (HAMA). Such samples may show either falsely elevated or falsely depressed values. This assay has been designed to minimize interference from heterophilic antibodies. Nevertheless, complete elimination of this interference from all patient specimens cannot be guaranteed. A test result that is inconsistent with the clinical picture and patient history should be interpreted with caution.

Specimens that contain biotin at a concentration of $3 0 0 ~ \mathrm { { n g / m L } }$ demonstrate a less than $10 \%$ change in results. Biotin concentrations greater than this may lead to falsely depressed results for patient samples.

Dextran 40 at $6 0 ~ \mathrm { g / L }$ increases the troponin result in plasma at $3 3 . 0 \ \mathrm { p g / m L \left[ n g / L \right] }$ and 1089.3 $\mathtt { p g / m L } \left[ \mathtt { n g / L } \right]$ by $1 6 \%$ and $4 \%$ respectively. Dextran 40 at $1 5 \mathrm { g / L }$ and $4 5 \ \mathrm { g / L }$ demonstrates less than $10 \%$ change in results when testing plasma samples at the concentrations stated above.

Protein Gamma Globulin at $6 \mathrm { g / d L }$ causes anomalous results in plasma at approximately 40 $\mathtt { p g / m L } \left[ \mathtt { n g / L } \right]$ and $1 0 0 0 \mathrm { p g / m L \left[ n g / L \right] }$ of troponin. Protein gamma globulin at $2 . 5 \ \mathrm { g } / \mathrm { d L }$ demonstrates less than $10 \%$ change in results when testing plasma samples at the concentrations stated above.

$f .$ Assay Cut-Off: See Clinical Sensitivity Section below.

2. Comparison Studies:

a. Method Comparison with Predicate Device: Not applicable.

b. Matrix Comparison: Not applicable.

3. Clinical Studies:

a. Clinical Sensitivity:

A clinical study was performed to evaluate the clinical performance of the device at the different clinical cut-offs (see section 5, Expected values/Reference range, below). A multicenter prospective study evaluated 2495 patients from emergency departments presenting with chest pain or equivalent symptoms suggestive of acute coronary syndromes. Final diagnoses were adjudicated by an independent panel of expert physicians using criteria consistent with the 2007 Universal Definition of Myocardial Infarction (MI). Serial samples were collected from patients presenting to the emergency department. The number of patients adjudicated with an MI was $1 3 \%$ (325/2498). The sample collection times were at 0 – 1.5 hours (from time since presentation) and at the following timepoint relative to the time from presentation: 1.5 to 2.5 hours, 2.5 to 3.5 hours, 3.5 to 4.5 hours, 4.5 to 6 hours, 6 to 9 hours, 9 to 24 hours, and greater than 24 hours after presentation to the emergency department. Investigators and adjudicators were blinded to the proposed device’s results. Adjudicators were also blinded to site diagnoses. All results presented below were based on the adjudicated diagnoses. Clinical performance was estimated at an overall cut-off (male and female combined 99th percentile upper reference limit (URL) cut-off) and male- and femalespecific URL cut-offs, calculated as described in Section 5, Expected values/Reference range, below. The results are summarized below.

Using the overall 99th percentile $( 6 0 . 4 \mathrm { p g / m L } )$ ), the following results were obtained for males and females combined:

<table><tr><td rowspan=2 colspan=1>Interval(hr)</td><td rowspan=1 colspan=2>Sensitivity</td><td rowspan=1 colspan=2>Specificity</td><td rowspan=1 colspan=2>PositivePredictive Value</td><td rowspan=1 colspan=2>NegativePredictive Value</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>0-&lt;1.5</td><td rowspan=1 colspan=1>78.3</td><td rowspan=1 colspan=1>70.7-84.3</td><td rowspan=1 colspan=1>92.9</td><td rowspan=1 colspan=1>91.2-94.4</td><td rowspan=1 colspan=1>61.0</td><td rowspan=1 colspan=1>53.7-67.9</td><td rowspan=1 colspan=1>96.8</td><td rowspan=1 colspan=1>95.5-97.8</td></tr><tr><td rowspan=1 colspan=1>≥ 1.5- &lt; 2.5</td><td rowspan=1 colspan=1>88.8</td><td rowspan=1 colspan=1>84.1-92.2</td><td rowspan=1 colspan=1>91.6</td><td rowspan=1 colspan=1>90.1-92.8</td><td rowspan=1 colspan=1>60.3</td><td rowspan=1 colspan=1>55.2-65.3</td><td rowspan=1 colspan=1>98.3</td><td rowspan=1 colspan=1>97.5-98.8</td></tr><tr><td rowspan=1 colspan=1>≥ 2.5- &lt; 3.5</td><td rowspan=1 colspan=1>89.9</td><td rowspan=1 colspan=1>85.0-93.4</td><td rowspan=1 colspan=1>90.6</td><td rowspan=1 colspan=1>89.0-92.1</td><td rowspan=1 colspan=1>58.1</td><td rowspan=1 colspan=1>52.5-63.5</td><td rowspan=1 colspan=1>98.4</td><td rowspan=1 colspan=1>97.6-99.0</td></tr><tr><td rowspan=1 colspan=1>≥ 3.5 - &lt; 4.5</td><td rowspan=1 colspan=1>92.4</td><td rowspan=1 colspan=1>86.8-95.7</td><td rowspan=1 colspan=1>91.2</td><td rowspan=1 colspan=1>89.4-92.8</td><td rowspan=1 colspan=1>58.1</td><td rowspan=1 colspan=1>51.6-64.3</td><td rowspan=1 colspan=1>98.9</td><td rowspan=1 colspan=1>98.1-99.4</td></tr><tr><td rowspan=1 colspan=1>≥ 4.5-&lt;6</td><td rowspan=1 colspan=1>95.5</td><td rowspan=1 colspan=1>87.6-98.5</td><td rowspan=1 colspan=1>89.2</td><td rowspan=1 colspan=1>86.0-91.7</td><td rowspan=1 colspan=1>56.1</td><td rowspan=1 colspan=1>47.0-64.9</td><td rowspan=1 colspan=1>99.3</td><td rowspan=1 colspan=1>97.9-99.8</td></tr><tr><td rowspan=1 colspan=1>≥6-&lt;9</td><td rowspan=1 colspan=1>92.7</td><td rowspan=1 colspan=1>88.1-95.6</td><td rowspan=1 colspan=1>88.0</td><td rowspan=1 colspan=1>85.7-90.0</td><td rowspan=1 colspan=1>61.7</td><td rowspan=1 colspan=1>55.9-67.1</td><td rowspan=1 colspan=1>98.3</td><td rowspan=1 colspan=1>97.2-99.0</td></tr><tr><td rowspan=1 colspan=1>≥9-&lt;24</td><td rowspan=1 colspan=1>93.0</td><td rowspan=1 colspan=1>88.8-95.7</td><td rowspan=1 colspan=1>86.2</td><td rowspan=1 colspan=1>83.7-88.4</td><td rowspan=1 colspan=1>63.1</td><td rowspan=1 colspan=1>57.7-68.2</td><td rowspan=1 colspan=1>98.0</td><td rowspan=1 colspan=1>96.7-98.8</td></tr><tr><td rowspan=1 colspan=1>≥24</td><td rowspan=1 colspan=1>95.2</td><td rowspan=1 colspan=1>86.9-98.4</td><td rowspan=1 colspan=1>86.3</td><td rowspan=1 colspan=1>81.6-90.0</td><td rowspan=1 colspan=1>63.2</td><td rowspan=1 colspan=1>53.1-72.2</td><td rowspan=1 colspan=1>98.7</td><td rowspan=1 colspan=1>96.1-99.5</td></tr></table>

Using female-specific 99th percentile $\mathtt { 5 1 . 4 p g / m L } $ , the following results were obtained in females:

<table><tr><td rowspan=2 colspan=1>Interval(hr)</td><td rowspan=1 colspan=2>Sensitivity</td><td rowspan=1 colspan=2>Specificity</td><td rowspan=1 colspan=2>PositivePredictiveValue</td><td rowspan=1 colspan=2>NegativePredictive Value</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>0-&lt;1.5</td><td rowspan=1 colspan=1>83.3</td><td rowspan=1 colspan=1>69.4-91.7</td><td rowspan=1 colspan=1>94.6</td><td rowspan=1 colspan=1>92.0-96.4</td><td rowspan=1 colspan=1>61.4</td><td rowspan=1 colspan=1>48.4-72.9</td><td rowspan=1 colspan=1>98.2</td><td rowspan=1 colspan=1>96.4-99.1</td></tr><tr><td rowspan=1 colspan=1>≥ 1.5-&lt;2.5</td><td rowspan=1 colspan=1>91.0</td><td rowspan=1 colspan=1>82.6-95.6</td><td rowspan=1 colspan=1>91.9</td><td rowspan=1 colspan=1>89.7-93.7</td><td rowspan=1 colspan=1>54.6</td><td rowspan=1 colspan=1>46.0-62.9</td><td rowspan=1 colspan=1>99.0</td><td rowspan=1 colspan=1>97.9-99.5</td></tr><tr><td rowspan=1 colspan=1>≥ 2.5- &lt; 3.5</td><td rowspan=1 colspan=1>94.5</td><td rowspan=1 colspan=1>86.7-97.8</td><td rowspan=1 colspan=1>92.0</td><td rowspan=1 colspan=1>89.6-93.9</td><td rowspan=1 colspan=1>58.0</td><td rowspan=1 colspan=1>49.0-66.5</td><td rowspan=1 colspan=1>99.3</td><td rowspan=1 colspan=1>98.2-99.7</td></tr><tr><td rowspan=1 colspan=1>≥ 3.5 - &lt; 4.5</td><td rowspan=1 colspan=1>94.1</td><td rowspan=1 colspan=1>84.1-98.0</td><td rowspan=1 colspan=1>90.9</td><td rowspan=1 colspan=1>88.0-93.1</td><td rowspan=1 colspan=1>51.6</td><td rowspan=1 colspan=1>41.6-61.5</td><td rowspan=1 colspan=1>99.3</td><td rowspan=1 colspan=1>98.1-99.8</td></tr><tr><td rowspan=1 colspan=1>≥ 4.5-&lt;6</td><td rowspan=1 colspan=1>96.0</td><td rowspan=1 colspan=1>80.5-99.3</td><td rowspan=1 colspan=1>85.5</td><td rowspan=1 colspan=1>80.6-89.4</td><td rowspan=1 colspan=1>40.7</td><td rowspan=1 colspan=1>29.1-53.4</td><td rowspan=1 colspan=1>99.5</td><td rowspan=1 colspan=1>97.3-99.9</td></tr><tr><td rowspan=1 colspan=1>≥6-&lt;9</td><td rowspan=1 colspan=1>94.1</td><td rowspan=1 colspan=1>85.8-97.7</td><td rowspan=1 colspan=1>87.9</td><td rowspan=1 colspan=1>84.2-90.8</td><td rowspan=1 colspan=1>58.2</td><td rowspan=1 colspan=1>48.8-67.0</td><td rowspan=1 colspan=1>98.8</td><td rowspan=1 colspan=1>97.0-99.5</td></tr><tr><td rowspan=1 colspan=1>≥9-&lt;24</td><td rowspan=1 colspan=1>93.1</td><td rowspan=1 colspan=1>84.8-97.0</td><td rowspan=1 colspan=1>88.5</td><td rowspan=1 colspan=1>84.7-91.4</td><td rowspan=1 colspan=1>62.6</td><td rowspan=1 colspan=1>53.2-71.2</td><td rowspan=1 colspan=1>98.4</td><td rowspan=1 colspan=1>96.3-99.3</td></tr><tr><td rowspan=1 colspan=1>≥24</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>87.1-100.0</td><td rowspan=1 colspan=1>82.0</td><td rowspan=1 colspan=1>73.8-88.0</td><td rowspan=1 colspan=1>56.5</td><td rowspan=1 colspan=1>42.2-69.8</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>95.9-100.0</td></tr></table>

Using the male-specific 99th percentile $\mathrm { 7 6 . 2 p g / m L ) }$ , the following results were obtained in males:

<table><tr><td rowspan=2 colspan=1>Interval(hr)</td><td rowspan=1 colspan=2>Sensitivity</td><td rowspan=1 colspan=2>Specificity</td><td rowspan=1 colspan=2>PositivePredictiveValue</td><td rowspan=1 colspan=2>NegativePredictiveValue</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>0-&lt;1.5</td><td rowspan=1 colspan=1>74.0</td><td rowspan=1 colspan=1>64.4-81.7</td><td rowspan=1 colspan=1>92.3</td><td rowspan=1 colspan=1>89.8-94.2</td><td rowspan=1 colspan=1>61.7</td><td rowspan=1 colspan=1>52.6-70.1</td><td rowspan=1 colspan=1>95.5</td><td rowspan=1 colspan=1>93.4-96.9</td></tr><tr><td rowspan=1 colspan=1>≥ 1.5- &lt; 2.5</td><td rowspan=1 colspan=1>85.2</td><td rowspan=1 colspan=1>78.9-89.8</td><td rowspan=1 colspan=1>92.5</td><td rowspan=1 colspan=1>90.6-94.0</td><td rowspan=1 colspan=1>66.3</td><td rowspan=1 colspan=1>59.7-72.4</td><td rowspan=1 colspan=1>97.3</td><td rowspan=1 colspan=1>96.0-98.2</td></tr><tr><td rowspan=1 colspan=1>≥ 2.5-&lt;3.5</td><td rowspan=1 colspan=1>84.9</td><td rowspan=1 colspan=1>77.6-90.1</td><td rowspan=1 colspan=1>91.0</td><td rowspan=1 colspan=1>88.7-92.8</td><td rowspan=1 colspan=1>61.1</td><td rowspan=1 colspan=1>53.8-68.1</td><td rowspan=1 colspan=1>97.3</td><td rowspan=1 colspan=1>95.8-98.3</td></tr><tr><td rowspan=1 colspan=1>≥ 3.5- &lt; 4.5</td><td rowspan=1 colspan=1>86.0</td><td rowspan=1 colspan=1>77.5-91.6</td><td rowspan=1 colspan=1>92.7</td><td rowspan=1 colspan=1>90.3-94.5</td><td rowspan=1 colspan=1>64.5</td><td rowspan=1 colspan=1>55.8-72.4</td><td rowspan=1 colspan=1>97.7</td><td rowspan=1 colspan=1>96.1-98.7</td></tr><tr><td rowspan=1 colspan=1>≥ 4.5-&lt;6</td><td rowspan=1 colspan=1>88.1</td><td rowspan=1 colspan=1>75.0-94.8</td><td rowspan=1 colspan=1>91.4</td><td rowspan=1 colspan=1>87.0-94.4</td><td rowspan=1 colspan=1>66.1</td><td rowspan=1 colspan=1>53.0-77.1</td><td rowspan=1 colspan=1>97.6</td><td rowspan=1 colspan=1>94.5-99.0</td></tr><tr><td rowspan=1 colspan=1>≥6-&lt;9</td><td rowspan=1 colspan=1>88.6</td><td rowspan=1 colspan=1>81.8-93.1</td><td rowspan=1 colspan=1>90.9</td><td rowspan=1 colspan=1>88.1-93.0</td><td rowspan=1 colspan=1>69.0</td><td rowspan=1 colspan=1>61.4-75.7</td><td rowspan=1 colspan=1>97.2</td><td rowspan=1 colspan=1>95.4-98.3</td></tr><tr><td rowspan=1 colspan=1>≥9-&lt;24</td><td rowspan=1 colspan=1>90.9</td><td rowspan=1 colspan=1>85.1-94.6</td><td rowspan=1 colspan=1>87.2</td><td rowspan=1 colspan=1>84.0-89.9</td><td rowspan=1 colspan=1>67.0</td><td rowspan=1 colspan=1>60.1-73.2</td><td rowspan=1 colspan=1>97.1</td><td rowspan=1 colspan=1>95.1-98.3</td></tr><tr><td rowspan=1 colspan=1>≥24</td><td rowspan=1 colspan=1>89.2</td><td rowspan=1 colspan=1>75.3-95.7</td><td rowspan=1 colspan=1>91.0</td><td rowspan=1 colspan=1>85.3-94.7</td><td rowspan=1 colspan=1>71.7</td><td rowspan=1 colspan=1>57.5-82.7</td><td rowspan=1 colspan=1>97.1</td><td rowspan=1 colspan=1>92.7-98.9</td></tr></table>

The following statements about cut-offs are included in the labeling:

Using the lower female-specific 99th percentile instead of the overall 99th percentile of 60.4 $\mathrm { { \sf p g / m L } }$ $( \mathrm { n g / L } )$ may result in a higher proportion of positive test results for females that are non-MI. Taking into consideration the lower bound of the $9 5 \%$ confidence interval, in the worst-case scenario ( drawn at ${ \ge } 4 . 5 \mathrm { - - } 1 6$ hours after presentation), up to $71 \%$ of positive test results for females may be non-MI.

Using the higher male-specific 99th percentile instead of the overall 99th percentile of 60.4 $\mathrm { { \sf p g / m L } }$ $( \mathrm { n g / L } )$ may result in a higher proportion of negative test results for males that are MI. For males that are MI, data analyzed using the male-specific cutoff versus the overall cutoff increased the false- negative rate by up to $3 . 3 \%$ .

b. Clinical Specificity:

See Clinical Sensitivity Section above.

4. Clinical Cut-Off:

The cut-offs for this assay were determined based on the 99th percentile upper reference limit in apparently healthy adults. Please see section 5, Expected Values/Reference Range, below for the determination of the clinical cut-offs.

# 5. Expected Values/Reference Range:

The sponsor conducted a multicenter prospective study to establish the 99th percentile in a population of apparently healthy adults.

Lithium-heparin plasma specimens were collected from apparently healthy adults with no known diseases of the cardiovascular system or other serious acute or chronic diseases or infections from the United States who ranged in age from 22–91 years of age.

Plasma samples from 2020 subjects were tested in singlicate. The 99th percentile value for results in apparently healthy subjects was calculated. The 99th percentile values were determined using the non-parametric empirical univariate distribution function. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>99th PercentileURL pg/mL [ng/L]</td><td rowspan=1 colspan=1>90% CI pg/mL[ng/L]</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>2020</td><td rowspan=1 colspan=1>60.4</td><td rowspan=1 colspan=1>43.2 to 81.3</td></tr><tr><td rowspan=1 colspan=1>Females</td><td rowspan=1 colspan=1>1017</td><td rowspan=1 colspan=1>51.4</td><td rowspan=1 colspan=1>35.6 to 109.2</td></tr><tr><td rowspan=1 colspan=1>Males</td><td rowspan=1 colspan=1>1003</td><td rowspan=1 colspan=1>76.2</td><td rowspan=1 colspan=1>42.3 to 117.0</td></tr></table>

# VIII Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.